Assessment of the potential interactions between favipiravir and radiocontrast agents

Table 1 Change of mean age values according to drug interaction status, mean ± SD

	Patients with drug interactions	Patients without drug interactions	Whole population	χ2 P value
Age (yr)	58.28 ± 7.44	46.77 ± 8.16	47.23 ± 9.48	0.003a

^aP < 0.05.

Table 2 Change of gender according to drug interaction status, n (%)

Gender	Patients with drug interactions	Patients without drug interaction	Whole population	χ2 P value
Female	26 (3.9)	625 (96.1)	651	0.090
Male	16 (4)	379 (96)	395

Table 3 Use of magnetic resonance imaging contrast agents, n (%)

MRI contrast agent	Number of patients
Meglumine gadoterate	158 (56.2)
Gadoxetic acid disodium	123 (43.8)
Total	281 (100)

MRI: Magnetic resonance imaging.

Table 4 Drug interaction status by radiocontrast agent types, n (%)

Radiocontrast agent type	Patients with drug interactions	Patients without drug interaction	Whole population	χ2 P value
CT	29 (3.7)	736 (96.3)	765	0.001a
MRI	13 (4.6)	268 (95.4)	281

^aP < 0.05.

MRI: Magnetic resonance imaging; CT: Computed tomography.

Table 5 The incidence of drug interactions according to magnetic resonance imaging contrast agents, n (%)

MRI radiocontrast agent type	Patients with drug interactions	Patients without drug interaction	Whole population	χ2 P value
Gadoxetic acid disodium	10 (8.1)	113 (91.9)	123	0.001a
Meglumine gadoterate	3 (1.8)	155 (98.2)	158

^aP < 0.05.

MRI: Magnetic resonance imaging.